Founded by Drs. Scott Husson and Jinxiang Zhou in 2013, the idea for the company was inspired by research from over a decade of investigation at Clemson University. Purilogics develops and produces best-in-class membrane technologies for the rapidly growing biopharmaceutical industry. Our core value proposition is that our Purexa™️ series products will improve the speed of early stage development to get biologics to market faster where they are needed to service the large and growing population of patients with long-term, chronic conditions such as cancers, cardiovascular diseases, and autoimmune disorders. Market entry will result from use of these products in research and early stage development laboratories, where rapid drug purification is essential to discovery.
Purilogics is located within the Institute for Translational Oncology Research (ITOR) on the Prisma Health Upstate campus in Greenville, South Carolina. ITOR has extensive collaborative partnerships with the pharmaceutical industry, research universities, private sector companies, government agencies, oncology networks, and other strategic organizations.
Our expert team has received numerous awards and has raised millions in non-dilutive Small Business Innovation Research (SBIR) funding from the National Institutes of Health. As NSF I-Corps program graduates, the team has conducted nearly 200 customer discovery interviews to strengthen our business model.